CC
BMY icon

ClearArc Capital’s Bristol-Myers Squibb BMY Stock Holding History

ClearArc Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1.4M Sell
21,869
-475
-2% -$27.2K 0.55% 41
2019
Q3 		$1.13M Buy
22,344
+109
+0.5% +$5.12K 0.33% 72
2019
Q2 		$1.01M Sell
22,235
-2,907
-12% -$135K 0.3% 79
2019
Q1 		$1.2M Sell
25,142
-744
-3% -$37.1K 0.32% 73
2018
Q4 		$1.35M Sell
25,886
-11,810
-31% -$635K 0.4% 62
2018
Q3 		$2.34M Buy
37,696
+288
+0.8% +$17.1K 0.31% 80
2018
Q2 		$2.07M Buy
37,408
+192
+0.5% +$10.4K 0.29% 87
2018
Q1 		$2.35M Hold
37,216
– – 0.36% 70
2017
Q4 		$2.28M Buy
37,216
+56
+0.2% +$3.5K 0.31% 76
2017
Q3 		$2.37M Sell
37,160
-169
-0.5% -$9.87K 0.36% 70
2017
Q2 		$2.08M Sell
37,329
-505
-1% -$27.5K 0.34% 70
2017
Q1 		$2.06M Buy
37,834
+292
+0.8% +$16K 0.34% 74
2016
Q4 		$2.19M Sell
37,542
-406
-1% -$22.2K 0.39% 67
2016
Q3 		$2.05M Sell
37,948
-486
-1% -$31.2K 0.39% 63
2016
Q2 		$2.83M Buy
38,434
+4
+0% +$283 0.55% 50
2016
Q1 		$2.46M Buy
38,430
+102
+0.3% +$6.43K 0.52% 46
2015
Q4 		$2.64M Buy
38,328
+846
+2% +$55.9K 0.55% 44
2015
Q3 		$2.22M Sell
37,482
-648
-2% -$41.1K 0.46% 53
2015
Q2 		$2.54M Buy
38,130
+4,408
+13% +$290K 0.46% 51
2015
Q1 		$2.17M Buy
33,722
+172
+0.5% +$10.8K 0.45% 56
2014
Q4 		$1.98M Buy
33,550
+1,749
+5% +$98.6K 0.4% 67
2014
Q3 		$1.63M Buy
31,801
+659
+2% +$32.9K 0.37% 76
2014
Q2 		$1.51M Buy
31,142
+417
+1% +$20.6K 0.35% 86
2014
Q1 		$1.6M Buy
30,725
+46
+0.1% +$2.45K 0.39% 73
2013
Q4 		$1.63M Buy
30,679
+1,522
+5% +$77.5K 0.42% 67
2013
Q3 		$1.35M Sell
29,157
-8,305
-22% -$365K 0.38% 74
2013
Q2 		$1.67M Buy
+37,462
New +$1.63M 0.45% 59

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearArc Capital's BMY Position: Q4 2019 in Review

ClearArc Capital reduced its Bristol-Myers Squibb (BMY) stake by 2.1% in Q4 2019, selling an estimated $27.2K and leaving 21,869 shares worth $1.4M. The position accounts for 0.55% of the portfolio, ranked #41.

ClearArc Capital first reported a position in BMY in Q2 2013 and has held it in 27 quarters since. The position peaked at $2.83M in Q2 2016. 2,218 funds tracked by Wall St. Rank hold BMY as of Q4 2019.

  • ClearArc Capital held 21,869 shares of Bristol-Myers Squibb worth $1.4M as of Q4 2019.
  • ClearArc Capital sold 475 Bristol-Myers Squibb shares in Q4 2019, an estimated $27.2K.
  • Bristol-Myers Squibb made up 0.55% of ClearArc Capital's portfolio in Q4 2019, its #41 holding.
  • ClearArc Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 27 quarters since.
  • ClearArc Capital's Bristol-Myers Squibb position peaked at $2.83M in Q2 2016.
  • 2,218 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2019.

Based on ClearArc Capital's 13F filing for Q4 2019, filed 14 Feb 2020.